Posters

Evaluation of a trifocal multifocal intraocular lens in a bi-toric and a non-toric version over a 36 month follow-up period

Poster Details

First Author: I.Tarib MOROCCO

Co Author(s):    D. Breyer   S. Abdassalam   M. Gerl   G. Auffarth   F. Kretz        

Abstract Details

Purpose:

To evaluate the functional outcome after implantation of a trifocal MIOL in a bi-toric (AT LISA 939MP, Carl Zeiss Meditech, Germany) and a non-toric (AT LISA 839MP, Carl Zeiss Meditech, Germany) version over 36month follow up period.

Setting:

Augenärzte Gerl, Kretz & Kollegen, Standort Rheine, Germany

Methods:

In a prospective study patients receiving either a trifocal IOL (AT LISA tri 839, Carl Zeiss Meditech AG, Germany) or a toric, trifocal IOL (AT LISA tri 939, Carl Zeiss Meditech AG, Germany) have been followed over a time period of 3 years. Examinations included UDVA, UIVA, UNVA, CDVA, DCIVA and DCNVA [logMAR]. Additionally, a Salzburg Reading Desk (SRD) evaluation (uncorrected and distance corrected) was performed.

Results:

In the toric group the median postoperative binocular UDVA, UIVA and UNVA were 0.02, 0.04 and 0.10 compared to a CDVA, DCIVA and DCNVA of 0.04, -0.10 and -0.10 [logMAR]. The non-toric group showed a UDVA, UIVA and UNVA of 0.06, 0.09 and 0.06 compared to a CDVA, DCIVA and DCNVA of 0.04, 0.00 and 0.06 [logMAR], respectively.

Conclusions:

Both MIOLs offer a restoration of the visual function in multiple distances. The bitoricity of the toric version additionally offers a good compensation for corneal astigmatism.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non-monetary benefits from a competing company., receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company